R. Moncayo, Carmen https://orcid.org/0009-0004-5427-7336
Restuadi, Restuadi https://orcid.org/0000-0001-8434-4465
Zhang, Guanying
Marks, Daniel https://orcid.org/0000-0002-8641-193X
Ortega-Prieto, Paula
Doherty, Emily https://orcid.org/0009-0008-7881-9573
Lambie, Nathalie https://orcid.org/0009-0005-0440-5894
Whilding, Chad
Andrew, Ivan
Montoya, Alex https://orcid.org/0000-0002-6501-883X
Patel, Bhavik
Tyson, Katie https://orcid.org/0009-0007-0339-514X
Pennycook, Betheney R. https://orcid.org/0000-0001-5721-6994
Pendergast, Lauren
Wu, Vincen
Takats, Zoltan https://orcid.org/0000-0002-0795-3467
Matthews, Nik https://orcid.org/0000-0002-0602-1131
Young, George R. https://orcid.org/0000-0002-1203-588X
Verma, Priyanka https://orcid.org/0000-0002-2852-0767
Shliaha, Pavel https://orcid.org/0000-0003-3092-0724
Game, Laurence
Lenhard, Boris https://orcid.org/0000-0002-1114-1509
McNeish, Iain https://orcid.org/0000-0002-9387-7586
Fotopoulou, Christina
Barr, Alexis R. https://orcid.org/0000-0002-6684-8114
Cunnea, Paula https://orcid.org/0000-0002-3699-4911
Hall, Zoe https://orcid.org/0000-0002-1434-8329
Fets, Louise https://orcid.org/0000-0002-0317-2540
Funding for this research was provided by:
Cancer Research UK (RCCCEA-Nov21\100001)
RCUK | Medical Research Council (MC-A564-5QC70)
RCUK | Medical Research Council (MR/W019132/1)
Victoria’s Secret Global Fund for Women’s Cancers Career Development Award, in partnership with Pelotonia and AACR
Article History
Received: 31 May 2025
Accepted: 24 February 2026
First Online: 17 March 2026
Competing interests
: The Authors declare the following competing interests: I.M. has undertaken advisory boards for AstraZeneca, Clovis Oncology/pharma& and GSK. Imperial College has received institutional grant support from AstraZeneca. All other authors declare no competing interests.